-
1
-
-
58249095024
-
ATM activation and signaling under hypoxic conditions
-
Bencokova Z., Kaufmann M.R., Pires I.M., Lecane P.S., Giaccia A.J., Hammond E.M. ATM activation and signaling under hypoxic conditions. Mol. Cell. Biol. 2009, 29:526-537.
-
(2009)
Mol. Cell. Biol.
, vol.29
, pp. 526-537
-
-
Bencokova, Z.1
Kaufmann, M.R.2
Pires, I.M.3
Lecane, P.S.4
Giaccia, A.J.5
Hammond, E.M.6
-
2
-
-
84884129997
-
RNAi screens in mice identify physiological regulators of oncogenic growth
-
Beronja S., Janki P., Heller E., Lien W.-H., Keyes B.E., Oshimori N., Fuchs E. RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 2013, 501:185-190.
-
(2013)
Nature
, vol.501
, pp. 185-190
-
-
Beronja, S.1
Janki, P.2
Heller, E.3
Lien, W.-H.4
Keyes, B.E.5
Oshimori, N.6
Fuchs, E.7
-
3
-
-
77954238710
-
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
-
Boiko A.D., Razorenova O.V., van de Rijn M., Swetter S.M., Johnson D.L., Ly D.P., Butler P.D., Yang G.P., Joshua B., Kaplan M.J., et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
-
(2010)
Nature
, vol.466
, pp. 133-137
-
-
Boiko, A.D.1
Razorenova, O.V.2
van de Rijn, M.3
Swetter, S.M.4
Johnson, D.L.5
Ly, D.P.6
Butler, P.D.7
Yang, G.P.8
Joshua, B.9
Kaplan, M.J.10
-
4
-
-
84873739385
-
A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
-
Brooks K., Oakes V., Edwards B., Ranall M., Leo P., Pavey S., Pinder A., Beamish H., Mukhopadhyay P., Lambie D., Gabrielli B. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2013, 32:788-796.
-
(2013)
Oncogene
, vol.32
, pp. 788-796
-
-
Brooks, K.1
Oakes, V.2
Edwards, B.3
Ranall, M.4
Leo, P.5
Pavey, S.6
Pinder, A.7
Beamish, H.8
Mukhopadhyay, P.9
Lambie, D.10
Gabrielli, B.11
-
5
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
BRIM-3 Study Group
-
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
-
(2011)
N.Engl. J. Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
-
6
-
-
84870218588
-
DNA repair dysregulation from cancer driver to therapeutic target
-
Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 801-817
-
-
Curtin, N.J.1
-
7
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
-
8
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
Tutt, A.N.J.4
Johnson, D.A.5
Richardson, T.B.6
Santarosa, M.7
Dillon, K.J.8
Hickson, I.9
Knights, C.10
-
9
-
-
84859428543
-
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
-
Ferrao P.T., Bukczynska E.P., Johnstone R.W., McArthur G.A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2011, 31:1661-1672.
-
(2011)
Oncogene
, vol.31
, pp. 1661-1672
-
-
Ferrao, P.T.1
Bukczynska, E.P.2
Johnstone, R.W.3
McArthur, G.A.4
-
10
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
METRIC Study Group
-
Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N.Engl. J. Med. 2012, 367:107-114. METRIC Study Group.
-
(2012)
N.Engl. J. Med.
, vol.367
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
Nathan, P.4
Garbe, C.5
Milhem, M.6
Demidov, L.V.7
Hassel, J.C.8
Rutkowski, P.9
Mohr, P.10
-
11
-
-
84877601429
-
Heterogeneous differentiation patterns of individual CD8+ Tcells
-
Gerlach C., Rohr J.C., Perié L., van Rooij N., van Heijst J.W.J., Velds A., Urbanus J., Naik S.H., Jacobs H., Beltman J.B., et al. Heterogeneous differentiation patterns of individual CD8+ Tcells. Science 2013, 340:635-639.
-
(2013)
Science
, vol.340
, pp. 635-639
-
-
Gerlach, C.1
Rohr, J.C.2
Perié, L.3
van Rooij, N.4
van Heijst, J.W.J.5
Velds, A.6
Urbanus, J.7
Naik, S.H.8
Jacobs, H.9
Beltman, J.B.10
-
12
-
-
0142120661
-
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin
-
Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., Koukourakis M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003, 13:493-501.
-
(2003)
Melanoma Res.
, vol.13
, pp. 493-501
-
-
Giatromanolaki, A.1
Sivridis, E.2
Kouskoukis, C.3
Gatter, K.C.4
Harris, A.L.5
Koukourakis, M.I.6
-
14
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A., Grob J.-J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.-J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
Rutkowski, P.7
Blank, C.U.8
Miller, W.H.9
Kaempgen, E.10
-
15
-
-
0141816881
-
Suppression of BRAF(V599E) in human melanoma abrogates transformation
-
Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
-
(2003)
Cancer Res.
, vol.63
, pp. 5198-5202
-
-
Hingorani, S.R.1
Jacobetz, M.A.2
Robertson, G.P.3
Herlyn, M.4
Tuveson, D.A.5
-
16
-
-
84873819555
-
Which drug, and when, for patients with BRAF-mutant melanoma?
-
Jang S., Atkins M.B. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol. 2013, 14:e60-e69.
-
(2013)
Lancet Oncol.
, vol.14
, pp. e60-e69
-
-
Jang, S.1
Atkins, M.B.2
-
17
-
-
2442665663
-
Gleevec: prototype or outlier?
-
Kaelin W.G. Gleevec: prototype or outlier?. Sci. STKE 2004, 2004:pe12.
-
(2004)
Sci. STKE
, vol.2004
, pp. pe12
-
-
Kaelin, W.G.1
-
18
-
-
25444497278
-
The concept of synthetic lethality in the context of anticancer therapy
-
Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 689-698
-
-
Kaelin, W.G.1
-
19
-
-
84878679199
-
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
-
Kaplon J., Zheng L., Meissl K., Chaneton B., Selivanov V.A., Mackay G., van der Burg S.H., Verdegaal E.M.E., Cascante M., Shlomi T., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
-
(2013)
Nature
, vol.498
, pp. 109-112
-
-
Kaplon, J.1
Zheng, L.2
Meissl, K.3
Chaneton, B.4
Selivanov, V.A.5
Mackay, G.6
van der Burg, S.H.7
Verdegaal, E.M.E.8
Cascante, M.9
Shlomi, T.10
-
20
-
-
40649126759
-
MTOR is activated in the majority of malignant melanomas
-
Karbowniczek M., Spittle C.S., Morrison T., Wu H., Henske E.P. mTOR is activated in the majority of malignant melanomas. J.Invest. Dermatol. 2008, 128:980-987.
-
(2008)
J.Invest. Dermatol.
, vol.128
, pp. 980-987
-
-
Karbowniczek, M.1
Spittle, C.S.2
Morrison, T.3
Wu, H.4
Henske, E.P.5
-
21
-
-
84655161946
-
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
-
Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 9-22
-
-
Keith, B.1
Johnson, R.S.2
Simon, M.C.3
-
22
-
-
84864877535
-
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells
-
Landau H.J., McNeely S.C., Nair J.S., Comenzo R.L., Asai T., Friedman H., Jhanwar S.C., Nimer S.D., Schwartz G.K. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol. Cancer Ther. 2012, 11:1781-1788.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 1781-1788
-
-
Landau, H.J.1
McNeely, S.C.2
Nair, J.S.3
Comenzo, R.L.4
Asai, T.5
Friedman, H.6
Jhanwar, S.C.7
Nimer, S.D.8
Schwartz, G.K.9
-
23
-
-
34447258682
-
Microenvironmental influences in melanoma progression
-
Lee J.T., Herlyn M. Microenvironmental influences in melanoma progression. J.Cell. Biochem. 2007, 101:862-872.
-
(2007)
J.Cell. Biochem.
, vol.101
, pp. 862-872
-
-
Lee, J.T.1
Herlyn, M.2
-
24
-
-
61449182121
-
Principles of cancer therapy: oncogene and non-oncogene addiction
-
Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
-
(2009)
Cell
, vol.136
, pp. 823-837
-
-
Luo, J.1
Solimini, N.L.2
Elledge, S.J.3
-
25
-
-
79651470785
-
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
-
Ma C.X., Janetka J.W., Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 2011, 17:88-96.
-
(2011)
Trends Mol. Med.
, vol.17
, pp. 88-96
-
-
Ma, C.X.1
Janetka, J.W.2
Piwnica-Worms, H.3
-
26
-
-
84859726248
-
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
-
Ma C.X., Cai S., Li S., Ryan C.E., Guo Z., Schaiff W.T., Lin L., Hoog J., Goiffon R.J., Prat A., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J.Clin. Invest. 2012, 122:1541-1552.
-
(2012)
J.Clin. Invest.
, vol.122
, pp. 1541-1552
-
-
Ma, C.X.1
Cai, S.2
Li, S.3
Ryan, C.E.4
Guo, Z.5
Schaiff, W.T.6
Lin, L.7
Hoog, J.8
Goiffon, R.J.9
Prat, A.10
-
27
-
-
84877947967
-
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
-
Ma C.X., Ellis M.J.C., Petroni G.R., Guo Z., Cai S.-R., Ryan C.E., Craig Lockhart A., Naughton M.J., Pluard T.J., Brenin C.M., et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res. Treat. 2013, 137:483-492.
-
(2013)
Breast Cancer Res. Treat.
, vol.137
, pp. 483-492
-
-
Ma, C.X.1
Ellis, M.J.C.2
Petroni, G.R.3
Guo, Z.4
Cai, S.-R.5
Ryan, C.E.6
Craig Lockhart, A.7
Naughton, M.J.8
Pluard, T.J.9
Brenin, C.M.10
-
28
-
-
70349536006
-
Invivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression
-
Meacham C.E., Ho E.E., Dubrovsky E., Gertler F.B., Hemann M.T. Invivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 2009, 41:1133-1137.
-
(2009)
Nat. Genet.
, vol.41
, pp. 1133-1137
-
-
Meacham, C.E.1
Ho, E.E.2
Dubrovsky, E.3
Gertler, F.B.4
Hemann, M.T.5
-
29
-
-
77953770987
-
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
-
Morgan M.A., Parsels L.A., Zhao L., Parsels J.D., Davis M.A., Hassan M.C., Arumugarajah S., Hylander-Gans L., Morosini D., Simeone D.M., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010, 70:4972-4981.
-
(2010)
Cancer Res.
, vol.70
, pp. 4972-4981
-
-
Morgan, M.A.1
Parsels, L.A.2
Zhao, L.3
Parsels, J.D.4
Davis, M.A.5
Hassan, M.C.6
Arumugarajah, S.7
Hylander-Gans, L.8
Morosini, D.9
Simeone, D.M.10
-
30
-
-
84880254869
-
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
-
Morris E.J., Jha S., Restaino C.R., Dayananth P., Zhu H., Cooper A., Carr D., Deng Y., Jin W., Black S., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3:742-750.
-
(2013)
Cancer Discov.
, vol.3
, pp. 742-750
-
-
Morris, E.J.1
Jha, S.2
Restaino, C.R.3
Dayananth, P.4
Zhu, H.5
Cooper, A.6
Carr, D.7
Deng, Y.8
Jin, W.9
Black, S.10
-
31
-
-
78650333871
-
Targeting hypoxic cells through the DNA damage response
-
Olcina M., Lecane P.S., Hammond E.M. Targeting hypoxic cells through the DNA damage response. Clin. Cancer Res. 2010, 16:5624-5629.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5624-5629
-
-
Olcina, M.1
Lecane, P.S.2
Hammond, E.M.3
-
32
-
-
80051923932
-
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
-
Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., Sethumadhavan S., Woo H.-K., Jang H.G., Jha A.K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476:346-350.
-
(2011)
Nature
, vol.476
, pp. 346-350
-
-
Possemato, R.1
Marks, K.M.2
Shaul, Y.D.3
Pacold, M.E.4
Kim, D.5
Birsoy, K.6
Sethumadhavan, S.7
Woo, H.-K.8
Jang, H.G.9
Jha, A.K.10
-
33
-
-
33745303045
-
Hypoxia signalling in cancer and approaches to enforce tumour regression
-
Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
-
(2006)
Nature
, vol.441
, pp. 437-443
-
-
Pouysségur, J.1
Dayan, F.2
Mazure, N.M.3
-
34
-
-
57349143739
-
Efficient tumour formation by single human melanoma cells
-
Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
-
(2008)
Nature
, vol.456
, pp. 593-598
-
-
Quintana, E.1
Shackleton, M.2
Sabel, M.S.3
Fullen, D.R.4
Johnson, T.M.5
Morrison, S.J.6
-
35
-
-
78249250559
-
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized
-
Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., Morrison S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
-
(2010)
Cancer Cell
, vol.18
, pp. 510-523
-
-
Quintana, E.1
Shackleton, M.2
Foster, H.R.3
Fullen, D.R.4
Sabel, M.S.5
Johnson, T.M.6
Morrison, S.J.7
-
36
-
-
77952502408
-
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth
-
Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
-
(2010)
Cell
, vol.141
, pp. 583-594
-
-
Roesch, A.1
Fukunaga-Kalabis, M.2
Schmidt, E.C.3
Zabierowski, S.E.4
Brafford, P.A.5
Vultur, A.6
Basu, D.7
Gimotty, P.8
Vogt, T.9
Herlyn, M.10
-
37
-
-
84896031764
-
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
-
Sausville E., Lorusso P., Carducci M., Carter J., Quinn M.F., Malburg L., Azad N., Cosgrove D., Knight R., Barker P., et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014, 73:539-549.
-
(2014)
Cancer Chemother. Pharmacol.
, vol.73
, pp. 539-549
-
-
Sausville, E.1
Lorusso, P.2
Carducci, M.3
Carter, J.4
Quinn, M.F.5
Malburg, L.6
Azad, N.7
Cosgrove, D.8
Knight, R.9
Barker, P.10
-
38
-
-
33746427040
-
Making progress through molecular attacks on cancer
-
Sawyers C.L. Making progress through molecular attacks on cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:479-482.
-
(2005)
Cold Spring Harb. Symp. Quant. Biol.
, vol.70
, pp. 479-482
-
-
Sawyers, C.L.1
-
39
-
-
38349165576
-
Identification of cells initiating human melanomas
-
Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
-
(2008)
Nature
, vol.451
, pp. 345-349
-
-
Schatton, T.1
Murphy, G.F.2
Frank, N.Y.3
Yamaura, K.4
Waaga-Gasser, A.M.5
Gasser, M.6
Zhan, Q.7
Jordan, S.8
Duncan, L.M.9
Weishaupt, C.10
-
40
-
-
53349143662
-
Dissecting Tcell lineage relationships by cellular barcoding
-
Schepers K., Swart E., van Heijst J.W.J., Gerlach C., Castrucci M., Sie D., Heimerikx M., Velds A., Kerkhoven R.M., Arens R., Schumacher T.N. Dissecting Tcell lineage relationships by cellular barcoding. J.Exp. Med. 2008, 205:2309-2318.
-
(2008)
J.Exp. Med.
, vol.205
, pp. 2309-2318
-
-
Schepers, K.1
Swart, E.2
van Heijst, J.W.J.3
Gerlach, C.4
Castrucci, M.5
Sie, D.6
Heimerikx, M.7
Velds, A.8
Kerkhoven, R.M.9
Arens, R.10
Schumacher, T.N.11
-
41
-
-
69449096005
-
Heterogeneity in cancer: cancer stem cells versus clonal evolution
-
Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
-
(2009)
Cell
, vol.138
, pp. 822-829
-
-
Shackleton, M.1
Quintana, E.2
Fearon, E.R.3
Morrison, S.J.4
-
42
-
-
77954217479
-
Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock"
-
Sharma S.V., Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem. Pharmacol. 2010, 80:666-673.
-
(2010)
Biochem. Pharmacol.
, vol.80
, pp. 666-673
-
-
Sharma, S.V.1
Settleman, J.2
-
43
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
Sawai, A.4
Getz, G.5
Basso, A.6
Ye, Q.7
Lobo, J.M.8
She, Y.9
Osman, I.10
-
44
-
-
33751301357
-
Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases
-
Syljuåsen R.G., Jensen S., Bartek J., Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res. 2006, 66:10253-10257.
-
(2006)
Cancer Res.
, vol.66
, pp. 10253-10257
-
-
Syljuåsen, R.G.1
Jensen, S.2
Bartek, J.3
Lukas, J.4
-
45
-
-
42949149240
-
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
-
Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 3041-3046
-
-
Tsai, J.1
Lee, J.T.2
Wang, W.3
Zhang, J.4
Cho, H.5
Mamo, S.6
Bremer, R.7
Gillette, S.8
Kong, J.9
Haass, N.K.10
|